Denali Therapeutics (DNLI) Receivables (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly Receivables of $1.6 million for Q1 2026, down 5.88% year-over-year from $1.7 million in Q1 2025, and little changed quarter-over-quarter from $1.6 million in Q4 2025.
Denali Therapeutics (DNLI) Receivables (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Receivables for 9 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 5.88% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 5.88% YoY), while the FY2025 annual figure was $2.2 million, changed 0.28% from the prior year.
- Receivables steadied at $1.6 million in Q1 2026 per DNLI's latest filing, from $1.6 million in the prior quarter.
- Across five years, Receivables topped out at $9.3 million in Q4 2022 and bottomed at $357000.0 in Q2 2022.
- Historically, Receivables has averaged $2.4 million across 5 years, with a median of $1.9 million in 2024.
- Annual changes were most pronounced in 2022 — Receivables plunged 97.87% — and 2023, when it jumped 852.38%.
- Denali Therapeutics' Receivables stood at $9.3 million in 2022, then plunged by 70.91% to $2.7 million in 2023, then retreated by 19.59% to $2.2 million in 2024, then declined by 26.3% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
- Business Quant data shows DNLI's Receivables at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.93 Mn |
| Mar 31, 2026 | 1.60 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.90 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 3.20 Mn |
| Dec 31, 2022 | 9.28 Mn |
| Jun 30, 2022 | 357,000.00 |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 1.19 Mn |
| Jun 30, 2021 | 16.79 Mn |
| Mar 31, 2021 | 2.51 Mn |